Chronic hypertension in pregnancy

Am J Obstet Gynecol. 2020 Jun;222(6):532-541. doi: 10.1016/j.ajog.2019.11.1243. Epub 2019 Nov 9.

Abstract

Chronic hypertension and associated cardiovascular disease are among the leading causes of maternal and perinatal morbidity and death in the United States. Chronic hypertension in pregnancy is associated with a host of adverse outcomes that include preeclampsia, cesarean delivery, cerebrovascular accidents, fetal growth restriction, preterm birth, and maternal and perinatal death. There are several key issues related to the diagnosis and management of chronic hypertension in pregnancy where data are limited and further research is needed. These challenges and recent guidelines for the management of chronic hypertension are reviewed. Well-timed pregnancies are of utmost importance to reduce the risks of chronic hypertension; long-acting reversible contraceptive options are preferred. Research to determine optimal blood pressure thresholds for diagnosis and treatment to optimize short- and long-term maternal and perinatal outcomes should be prioritized along with interventions to reduce extant racial and ethnic disparities.

Keywords: chronic hypertension; death; morbidity; preeclampsia.

Publication types

  • Review

MeSH terms

  • Adrenergic alpha-2 Receptor Agonists / therapeutic use
  • Adrenergic beta-Antagonists / therapeutic use
  • Antihypertensive Agents / therapeutic use*
  • Calcium Channel Blockers / therapeutic use
  • Cesarean Section
  • Chronic Disease
  • Delivery, Obstetric / methods*
  • Disease Management
  • Female
  • Fetal Growth Retardation / epidemiology
  • Gestational Age
  • Humans
  • Hypertension / diagnosis
  • Hypertension / epidemiology
  • Hypertension / therapy*
  • Long-Acting Reversible Contraception
  • Methyldopa / therapeutic use
  • Postnatal Care / methods
  • Pre-Eclampsia / epidemiology
  • Preconception Care / methods
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / diagnosis
  • Pregnancy Complications, Cardiovascular / epidemiology
  • Pregnancy Complications, Cardiovascular / therapy*
  • Premature Birth / epidemiology
  • Prenatal Care / methods
  • Severity of Illness Index
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use
  • Time Factors
  • Vasodilator Agents / therapeutic use

Substances

  • Adrenergic alpha-2 Receptor Agonists
  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Sodium Potassium Chloride Symporter Inhibitors
  • Vasodilator Agents
  • Methyldopa